Personalized Healthcare Tests Provide Genetic Information on Each Patient
By LabMedica International staff writers Posted on 19 Feb 2013 |
Image: genomic biomarkers can help to predict the efficacy and safety of specific treatments in individuals (Photo courtesy of Qiagen).
A broad collaboration agreement between two companies will allow the development and commercialization of companion diagnostics. Financial terms of the agreement are not disclosed.
Qiagen (Hilden, Germany) companion diagnostics is collaborating with Lilly medicines (Indianapolis, IN, USA) in an effort to improve outcomes for individual patients.
Companion diagnostics discover a patient’s molecular information in order to guide treatment decisions for specific cancers or other diseases. The agreement builds on Qiagen and Lilly’s past work together. It provides a framework for Lilly and Qiagen to collaborate on future projects, across all of Lilly’s therapeutic areas, aimed at bringing to market Lilly medicines paired with Qiagen diagnostics.
“Tailored therapies are a key component of Lilly’s strategy of providing improved outcomes for individual patients. By working with partners like Qiagen, we are advancing a number of tailored therapeutics in an effort to target the right medicine to the right patient,” said Daniel Skovronsky, MD, PhD, vice president, tailored therapeutics, Lilly, and CEO, Avid Radiopharmaceuticals, a wholly-owned subsidiary of Lilly. “This collaboration with Qiagen extends our capabilities to more quickly and cost-effectively bring innovative new medicines, alongside advanced diagnostics, to patients worldwide who are waiting.”
Qiagen and Lilly have previously collaborated on companion diagnostics designed to run on Qiagen's Rotor-Gene Q system, a component of the QIAsymphony family of automated instruments, which is revolutionizing laboratory workflows. Qiagen's strategy is to develop US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved diagnostics in the United States for use on this platform.
Related Links:
Qiagen
Lilly medicines
US Food and Drug Administration
Qiagen (Hilden, Germany) companion diagnostics is collaborating with Lilly medicines (Indianapolis, IN, USA) in an effort to improve outcomes for individual patients.
Companion diagnostics discover a patient’s molecular information in order to guide treatment decisions for specific cancers or other diseases. The agreement builds on Qiagen and Lilly’s past work together. It provides a framework for Lilly and Qiagen to collaborate on future projects, across all of Lilly’s therapeutic areas, aimed at bringing to market Lilly medicines paired with Qiagen diagnostics.
“Tailored therapies are a key component of Lilly’s strategy of providing improved outcomes for individual patients. By working with partners like Qiagen, we are advancing a number of tailored therapeutics in an effort to target the right medicine to the right patient,” said Daniel Skovronsky, MD, PhD, vice president, tailored therapeutics, Lilly, and CEO, Avid Radiopharmaceuticals, a wholly-owned subsidiary of Lilly. “This collaboration with Qiagen extends our capabilities to more quickly and cost-effectively bring innovative new medicines, alongside advanced diagnostics, to patients worldwide who are waiting.”
Qiagen and Lilly have previously collaborated on companion diagnostics designed to run on Qiagen's Rotor-Gene Q system, a component of the QIAsymphony family of automated instruments, which is revolutionizing laboratory workflows. Qiagen's strategy is to develop US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved diagnostics in the United States for use on this platform.
Related Links:
Qiagen
Lilly medicines
US Food and Drug Administration
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics